MedX Health Corp. ("MedX") (TSX-V: MDX) is pleased to announce the appointment of medical equipment industry executive Nick Hoffman as Director, Business Development, effective immediately. Mr. Hoffman will be working with the MedX team in managing customer acquisition and support initiatives as the Company commercializes and begins an aggressive installation phase for its SIAscopy on DermSecure™ telemedicine platform.
"Nick brings years of experience in healthcare sales, marketing and service management, working with start-ups and industry leading OEM’s scaling revenue and building partnerships," noted Scott Spearn, CEO of MedX. "We will be scaling rapidly as the demand for telemedicine and remote assessment applications have come to the forefront, and working with customers and practitioners to implement our unique dermatologic platform, Nick’s success in serving customer needs will be important in this next phase of our growth."
Mr. Hoffman’s has spent most of his career in the healthcare diagnostic imaging industry, including roles with radiology, teleradiology and digital imaging companies in product support, product sales management, business strategy, business development and marketing. He has proven expertise in assisting companies through start-up to revenue generation, product sales and distribution and value creation at companies such as, Johnson and Johnson, GE Healthcare, Siemens Healthcare and a variety of university-based start-up companies.
Currently, between two and three million non-melanoma skin cancers and 300,000 melanoma skin cancers occur globally each year. One in every three cancers diagnosed is a skin cancer and, according to Skin Cancer Foundation Statistics, one in every five people will develop skin cancer in their lifetime. The global demand for SIAscopy on DermSecure™ will continue to increase with the growth of telemedicine and as early detection is recognized as the way to optimize survival and reduce healthcare costs.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union and Turkey. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.
Scott Spearn, President and CEO
MedX Health Corp
905-670-4428 ext 229